Difference between revisions of "Aldesleukin (Proleukin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[https://online.lexi.com/lco/action/login UpToDate Lexidrug]" to "UpToDate Lexidrug")
 
(38 intermediate revisions by 5 users not shown)
Line 1: Line 1:
−
Also known as interleukin-2, IL-2.
 
−
 
 
==General information==
 
==General information==
−
Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.<ref name="insert">[http://www.proleukin.com/assets/proleukin.pdf Aldesleukin (Proleukin) package insert]</ref><ref>[[Media:Aldesleukin.pdf | Aldesleukin (Proleukin) package insert (locally hosted backup)]]</ref><ref>[http://www.proleukin.com/ Proleukin manufacturer's website]</ref>
+
Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.<ref name="insert">[https://www.proleukin.com/downloads/proleukin-pi.pdf Aldesleukin (Proleukin) package insert]</ref><ref>[[:File:Aldesleukin.pdf | Aldesleukin (Proleukin) package insert (locally hosted backup)]]</ref><ref>[http://www.proleukin.com/ Proleukin manufacturer's website]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: no information
 
<br>Extravasation: no information
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/interleukin-2-proleukin-aldesleukin-342203 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, [http://reference.medscape.com/drug/interleukin-2-proleukin-aldesleukin-342203 Medscape], or the prescribing information.<ref name="insert"></ref>
 +
 
 +
==Diseases for which it is established ''(work in progress)''==
 +
*[[Renal cell carcinoma]]
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
−
*[[Bone cancer]]
 
 
*[[Melanoma]]
 
*[[Melanoma]]
−
*[[Renal cancer]]
+
*[[Neuroblastoma]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://chemocare.com/chemotherapy/drug-info/aldesleukin.aspx Aldesleukin (Proleukin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/aldesleukin.aspx Aldesleukin (Proleukin) patient drug information (Chemocare)]</ref>
+
*[https://chemocare.com/druginfo/aldesleukin.aspx Aldesleukin (Proleukin) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/aldesleukin.aspx Aldesleukin (Proleukin) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/aldesleukin-patient-drug-information Aldesleukin (Proleukin) patient drug information (UpToDate)]</ref>
 +
 +
 +
==History of changes in FDA indication==
 +
*1992-05-05: Initial approval for treatment of adults (>18 years old) with metastatic [[renal cell carcinoma]]. ''(Based on Fyfe et al. 1995)''
 +
*Uncertain date: Approved for the treatment of adults with metastatic [[melanoma]]. ''(Based on Atkins et al. 1999)''
 +
==History of changes in EMA indication==
 +
*1989-07-03: EURD
 +
==History of changes in PMDA indication==
 +
*2021-06-23: New indication and a new dosage for the enhancement of an antitumor effect of dinutuximab (genetical recombination) for [[neuroblastoma]].
 +
==Also known as==
 +
*'''Code name:''' ILT-101
 +
*'''Generic names:''' Interleukin-2, IL-2
 +
*'''Brand names:''' Macrolin, Proleukin, Teceleukin
  
 
==References==
 
==References==
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
−
[[Category:Chemotherapy]]
+
[[Category:Intravenous medications]]
−
[[Category:Immunotherapy]]
+
 
−
[[Category:Bone cancer medications]]  
+
[[Category:Interleukins]]
−
[[Category:Melanoma medications]]  
+
[[Category:T-cell activators]]
−
[[Category:Renal cancer medications]]
+
 
 +
[[Category:Melanoma medications]]
 +
[[Category:Neuroblastoma medications]]  
 +
[[Category:Renal_cell_carcinoma medications]]
 +
 
 +
[[Category:FDA approved in 1992]]
 +
[[Category:EMA approved in 1989]]

Latest revision as of 00:15, 6 July 2024

General information

Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information


History of changes in FDA indication

  • 1992-05-05: Initial approval for treatment of adults (>18 years old) with metastatic renal cell carcinoma. (Based on Fyfe et al. 1995)
  • Uncertain date: Approved for the treatment of adults with metastatic melanoma. (Based on Atkins et al. 1999)

History of changes in EMA indication

  • 1989-07-03: EURD

History of changes in PMDA indication

  • 2021-06-23: New indication and a new dosage for the enhancement of an antitumor effect of dinutuximab (genetical recombination) for neuroblastoma.

Also known as

  • Code name: ILT-101
  • Generic names: Interleukin-2, IL-2
  • Brand names: Macrolin, Proleukin, Teceleukin

References

  1. ↑ 1.0 1.1 Aldesleukin (Proleukin) package insert
  2. ↑ Aldesleukin (Proleukin) package insert (locally hosted backup)
  3. ↑ Proleukin manufacturer's website
  4. ↑ Aldesleukin (Proleukin) patient drug information (Chemocare)
  5. ↑ Aldesleukin (Proleukin) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Aldesleukin_(Proleukin)&oldid=88549"